



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 54929

**Title:** Progress in immunotherapy for small cell lung cancer

**Reviewer's code:** 04761856

**Position:** Peer Reviewer

**Academic degree:** MD, MSc

**Professional title:** Assistant Professor

**Reviewer's Country/Territory:** South Korea

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-02-26

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-02-26 21:41

**Reviewer performed review:** 2020-03-06 08:29

**Review time:** 8 Days and 10 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

This manuscript is well written, seems conducted by experienced medical researcher and practitioner. I have no objection to the contents and subject of manuscript. but I have two minor revisions for perfection: 1) although the contents are fine, some tables or figures which can summarize information of which authors want to emphasize are necessary. 2) two key components of treatment of SCLC is systemic and radiation therapy, as authors also suggested. But no radiotherapy content is found. I recommend to add a small section about the recent RT indication for SCLC, or ongoing studies regarding combination of immunotherapy and radiotherapy. (probably latter will be nicer)



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 54929

**Title:** Progress in immunotherapy for small cell lung cancer

**Reviewer's code:** 00291404

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Associate Professor, Professor

**Reviewer's Country/Territory:** United States

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-02-26

**Reviewer chosen by:** Jin-Zhou Tang

**Reviewer accepted review:** 2020-03-13 12:55

**Reviewer performed review:** 2020-03-13 17:22

**Review time:** 4 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

#### **SPECIFIC COMMENTS TO AUTHORS**

The authors have done a very good job in reviewing the recent clinical studies of immunotherapy for small cell lung cancer. There are only a few essential minor things which need to be taken care of before publication. Minor Issues: 1. Page 4 (Under IL-2 section): “cytotoxic T cells do not enter the immune microenvironment”. You really mean “tumor microenvironment”? 2. Page 4, Under “Vaccines” section. Chemotherapy may be immunoinhibitory or immunostimulatory, depending on: (1). Type of chemotherapeutic agents. Some agents induce immunogenic cell death, and therefore they are immunostimulatory while others are inhibitory. (2). The dose used. Usually higher doses kill immune cells and thus immunoinhibitory. 3. Page 5, line 9 from the bottom. In “For example, expression of tumor-infiltrating lymphocytes (TILs) in SCLC is...”, it seems that the word “expression” is an error. 4. Page 6, under “CTLA-4”. One of the major functions of CTLA-5 inhibitors is to inhibit regulatory T cells. Please add 1-2 sentences of discussion and cite 1-2 relevant papers here. 5. Ref #20. The one cited is just an abstract. The full paper has been published now: Carvajal-Hausdorf D, Altan M, Velcheti V, Gettinger SN, Herbst RS, Rimm DL, Schalper KA. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC). *J Immunother Cancer*. 2019 Mar 8;7(1):65. doi: 10.1186/s40425-019-0540-1. [PMID: 30850021] Please update.



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 54929

**Title:** Progress in immunotherapy for small cell lung cancer

**Reviewer's code:** 03004570

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Professor

**Reviewer's Country/Territory:** Turkey

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-02-26

**Reviewer chosen by:** Jin-Zhou Tang

**Reviewer accepted review:** 2020-03-14 21:54

**Reviewer performed review:** 2020-03-19 06:51

**Review time:** 4 Days and 8 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

This manuscript is an invited minireview about the immunotherapy in small cell lung cancer. It contains clinically important up-to-date information. I recommend publishing. The article needs some small corrections; first correction should be made in pp#4; the word “natural” should be added before IFN-a such as “Group B received chemotherapy + natural IFN-a”, and second correction should be made as “the OS was 13.0 months with Durvalumab plus platinum+etoposide and 10.3 months with platinum+etoposide” in the Durvalumab section in pp#10 & 11.